Bio-Gate AG Logo

Bio-Gate AG

Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.

BIG1 | F

Overview

Corporate Details

ISIN(s):
DE000BGAG981
LEI:
391200G5LKTIOTZOXP90
Country:
Germany
Address:
Neumeyerstr. 28-34, 90411 Nürnberg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bio-Gate AG is a leading provider of innovative technologies and customized solutions for health and hygiene. The company specializes in developing and applying antimicrobial and antiviral strategies to enhance materials and products. Its core markets include medical technology, where it provides coatings for medical implants and wound dressings to prevent infections. Bio-Gate's technologies are also utilized in derma-cosmetics, veterinary medicine (featuring its MicroSilver BG™ technology), and a range of industrial and consumer goods such as paints, plastics, and textiles, improving safety and adding value to end products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-29 18:39
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.3 KB
2025-09-30 15:07
Earnings Release
Bio-Gate veroffentlicht Halbjahreszahlen und bestatigt den Ausblick fur 2025
German 11.4 KB
2025-09-11 20:04
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.1 KB
2025-08-21 17:58
Director's Dealing
Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen
German 6.0 KB
2025-08-19 17:50
Capital/Financing Update
Bio-Gate AG: Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unte…
German 6.2 KB
2025-08-12 17:40
Director's Dealing
Bio-Gate AG: Thomas Konradt, Zeichnung von Wandelschuldverschreibungen
German 5.9 KB
2025-07-31 21:17
Earnings Release
Bio-Gate veroffentlicht endgultige Zahlen 2024 und gibt positiven Ausblick fur …
German 13.0 KB
2025-06-03 21:13
Capital/Financing Update
Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unter Ausschluss …
German 8.4 KB
2025-04-08 09:56
Regulatory News Service
Bio-Gate starkt in Nordamerika Prasenz fur den Absatz von Tierpflegeprodukten f…
German 12.9 KB
2025-04-08 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 38.0 KB
2025-02-27 11:09
Regulatory News Service
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-26 11:09
Earnings Release
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-21 09:30
Regulatory News Service
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB

Automate Your Workflow. Get a real-time feed of all Bio-Gate AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bio-Gate AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bio-Gate AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.